Inflammation‑based prognostic markers of metastatic pancreatic cancer using real‑world data in Japan: The Tokushukai REAl‑world Data (TREAD) project
- Authors:
- Published online on: January 31, 2024 https://doi.org/10.3892/ol.2024.14269
- Article Number: 136
-
Copyright: © Shimoyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Pancreatic cancer is the fourth leading cause of cancer death and has one of the poorest prognoses, with a very low 5-year survival rate of about 10% in Japan and the United States (1–3). Its incidence is increasing (1,3), and most cases (−80%) are unresectable at diagnosis. FOLFIRINOX (including fluorouracil, folinic acid, oxaliplatin, and irinotecan) (4–6) and gemcitabine plus nab-paclitaxel (7) have been reported as the standard first-line therapies for advanced/recurrent pancreatic cancer, but the prognosis remains poor with median overall survival (OS) of 9–12 months in clinical trials (4,7). Conversely, our real-world study, encompassing 846 cases of metastatic pancreatic cancer initially treated between 2010 and 2020, revealed a median OS of just 6.8 months (8).
Even in cases with unfavorable prognoses, an accurate prediction of the clinical outcomes is crucial. The usefulness of inflammation-based and nutritional markers in patients with cancer has been widely reported (9). Historically, various prognostic markers and their correlation with outcomes in cancer patients have been reported since the 1980s (10–12). To date, numerous markers have been investigated for their utility in diverse scenarios, and due to their convenience, they are widely utilized in actual clinical practice. Nonetheless, data on their direct comparisons are limited. It's essential to validate the most suitable markers for each specific clinical setting.
The objective of this study is to conduct a direct comparison of the various inflammation-based prognostic markers reported to date, utilizing the aforementioned dataset (8), in order to identify the most accurate markers for assessing prognosis in metastatic pancreatic cancer.
Patients and methods
Study overview
The Tokushukai Real-world Data (TREAD) project is a retrospective cohort study conducted at Tokushukai Medical Group hospitals. Tokushukai Medical Group is a leading medical group in Japan, encompassing 71 general hospitals nationwide. The study utilizes a shared medical record system across these hospitals. (e-Karte and Newtons2; Software Service Inc., Osaka, Japan) and chemotherapy protocol system (srvApmDrop; Software Service Inc., Osaka, Japan), the details of which can be found in a separate article (13). The project adhered to the ethical guidelines for medical and biological research involving human subjects in Japan (14) and followed the principles of the Declaration of Helsinki. Approval for the study was obtained from the Ethics Committee of the Tokushukai Group in April 2020 (approval no. TGE01427-024). Patients were informed about the opt-out method, and the study was registered in the UMIN Clinical Trial Registry under the number UMIN000050590.
Patients
We identified 846 patients with pathologically or radiologically confirmed primary metastatic pancreatic cancer who underwent first-line chemotherapy at Tokushukai Medical Group hospitals between April 1, 2010, and March 31, 2020 (8). Briefly, the patients were treated with gemcitabine, S-1, gemcitabine plus S-1, gemcitabine plus nab-paclitaxel, or FOLFIRINOX as their first-line treatment. Patients with pathological diagnoses of adenocarcinoma, adenosquamous carcinoma, and carcinoma/malignant neoplasms were included in the analysis. Patients with active double cancer, inadequate treatment history, and missing fundamental patient data were excluded from the study.
Data collection
As separately described, information on patients, tumor-related factors, study period (A: 2010–2013, B: 2014–2016, C: 2017–2020), hospital volume (high- and low-volume hospitals), hospital type (government-designated cancer hospital, prefecture-designated cooperative cancer hospital, or non-designated general hospital), and first-line chemotherapy regimens was extracted from the medical record system, the chemotherapy protocol system, and the National Cancer Registry Data in Japan (15).
For supplemental analysis, blood laboratory data for different parameters [white blood cells, neutrocytes, lymphocytes, monocytes, hemoglobin, platelets, total bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH), γ-glutamyl transpeptidase, alkaline phosphatase, creatinine, creatinine clearance, c-reactive protein (CRP), albumin, glucose, hemoglobin A1c, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9)] collected within 14 days of first-line treatment were extracted from the electronic medical record, and levels of inflammation-based prognostic markers were calculated (16–29). The markers used in this study are listed in Table I. For the markers, previously defined cutoff values were used, but for those that were not defined, we referred to previous studies (24,25).
Statistical analysis
Patients with complete data available were evaluated. The primary endpoint evaluated in the current study was OS, defined as the time from the start date of initial palliative chemotherapy to the date of death or final survival confirmation.
Basic statistics (absolute and relative frequencies for categorical variables; quartiles, maximum values, minimum values, means, or medians for continuous variables) were obtained to summarize the distribution of variables related to patient background factors, complications, other prognostic factors, and primary and secondary endpoints. Survival analyses were performed using OS as the primary endpoint. The censored cases included patients who were alive at the end date of the study or had dropped out of the study for any reason.
Kaplan-Meier curves (univariate analyses) were obtained for each inflammation-based prognostic markers associated with OS, and the log-rank test was utilized to compare survival curves. We compared the predictive quality of markers against OS using the Cox regression analysis concordance (rate) and the Akaike Information Criterion (AIC). Concordance was defined as follows. Assuming that (si, yi) is a pair of observed survival time (y) and scores (s), a pair of observations (i, j) was considered ‘concordant’ if (yi > yj, si < sj) or (yi < yj, si >sj), as these conditions are symmetrical. Conversely, it was considered ‘discordant’ if the conditions (yi < yj, si < sj) or (yi > yj, si > sj) applied. If c, d, and ts are counts of pairs that are concordant, discordant, or tied when using score s, then concordance C is defined as C=(c + ts/2)/(c + d + ts) using the proportion of concordant pairs. Although the above definition of ‘concordant’ and ‘discordant’ pairs appears to be reversed, survival is inversely correlated with the height of the hazard, and this definition has validity.
All analyses were performed using R, version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria). All statistical assessments were conducted as two-sided, and significance was determined with a threshold of P<0.05. All statistical analyses were two-sided, and P<0.05 was considered to indicate a statistically significant difference.
Results
Patients' characteristics
Among the 846 patients initially identified for this study, a total of 487 individuals were selected in the analysis due to the availability of complete data. Table II displays the characteristics of both the entire patient cohort and the subset included in the analysis. The two populations showed similar characteristics.
Comparison of the ratios and scores
Table III summarizes the OS statistics by 17 inflammation-based prognostic markers. All markers had statistically significant prognostic value. In addition, when comparing ratios computed as continuous variables with scores determined using categorical variables employing specific cutoff values, it was evident that similar hazard ratio (HR)s were observed. For instance, when we analyzed the HRs and their corresponding 95% confidential intervals for NLR (<3 compared to ≥3-<5 and ≥5) and NLS (0 compared to 1 and 2), the outcomes were as follows: 1.76 (1.35–2.29) and 2.67 (2.07–3.44) for NLR, and 1.60 (1.26–2.03) and 2.46 (1.75–3.47) for NLS, respectively.
Kaplan-Meier curves
The Kaplan-Meier curves for OS by each inflammation-based prognostic marker are shown in Fig. 1. Each marker alone showed a significant correlation with prognosis. Additionally, for the majority of markers, each increment in the numerical value was linked to a gradual deterioration in prognosis.
Comparison of the inflammation-based prognostic markers
The concordance rates and AICs calculated for the 17 inflammation-based prognostic markers are shown in Table IV. The concordance values ranged from 0.616 to 0.679, and the AIC values ranged from 3784 to 3836. Among them, the mGPS correlated best with OS, followed by GPS and lung immune prognostic index (LIPI).
Discussion
In this study, we compared inflammation-based prognostic markers helpful in predicting prognosis in patients undergoing chemotherapy for metastatic pancreatic cancer using real-world data from the Tokushukai medical database. While numerous prognostic and predictive markers have been reported, to the best of our knowledge, this study represents the most comprehensive comparison of inflammation-based prognostic markers to date. All 17 markers we evaluated demonstrated significant prognostic value, irrespective of whether they were ratio-based or scored systems. Among them, the mGPS, GPS, and LIPI emerged as the most accurate in predicting prognosis following first-line treatment of metastatic pancreatic cancer.
GPS is probably the most widely used prognostic score, with numerous reports supporting its usefulness. It was defined and reported by Forrest et al (17) in 2003 as CRP and albumin levels in patients with unresectable non-small cell lung cancer. According to multivariate analyses, the combined score of CRP and albumin was identified as an independent prognostic factor, and a validation study was subsequently reported in 2004 (30). The validity of the GPS has been reported in the Glasgow Inflammation Outcome Study (18,19), and the GPS is now widely used as an inflammation-based prognostic marker (11). In addition, several modifications of the GPS with adjusted cutoff values have been reported with improved accuracy. In studies of patients with colorectal cancer, low albumin levels did not correlate with poor prognosis because few patients have low albumin levels without elevated CRP levels. Thus, low albumin level alone looked less associated with poor prognosis (31), and a modified GPS that partially excludes the albumin level has been suggested (11). In a study examining the correlation between the mGPS and prognosis in Japanese patients with colorectal cancer, the best cutoff value of 0.5 mg/dl was reported for CRP based on its receiver operating characteristic curve (32).
LIPI, another recently reported score, is based on a combination of dNLR and LDH scores. The prognostic correlation of LIPI was reported by Mezquita et al in 2018 in patients treated with immune checkpoint inhibitors for advanced non-small cell lung cancer (28). LIPI has been developed as a prognostic score because dNLR and LDH level were independent prognostic factors in two large retrospective studies of patients with metastatic melanoma treated with ipilimumab (33) or pembrolizumab (34). The combination of these two factors has been reported to be of prognostic value in patients treated with immune checkpoint inhibitors for lung cancer (35,36), urothelial carcinoma (37), or solid tumors in general (38). Although the LIPI score was developed for patients treated with immune checkpoint inhibitors, the present study shows it is also a useful prognostic indicator in metastatic pancreatic cancer. The literature examining the usefulness of LIPI is still limited, and further studies are needed to determine whether it is reproducible in other cancers.
This study has a few limitations. First, due to the retrospective design, a number of patients had deficiencies in blood tests such as CRP, albumin, and LDH, which are not essential for chemotherapy induction. Accordingly, fewer patients qualified for the complete analysis. Second, new inflammation-based prognostic markers are introduced each year, and not all of them are included in this study. Third, this study included only Japanese subjects. Hence, its external validity may be limited in non-Asian populations. However, a nationwide study conducted in the Netherlands on metastatic pancreatic cancer identified CA19-9, albumin, CRP, LDH, C-reactive protein-to-albumin ratio, and GPS/mGPS as easily measurable prognostic biomarkers (39). Additionally, a systematic review from 2013 confirmed the prognostic potential of GPS/mGPS and NLR (40). Hence, it is safe to assume that at least GPS/mGPS are applicable prognostic biomarkers for both Asian and non-Asian patients with metastatic pancreatic cancer.
Lastly, additional parameters such as hemoglobin, CEA, and CA19-9 may also hold prognostic significance. Despite these limitations, the robustness of this study lies in the incorporation of a sizable cohort and the simultaneous assessment of real-world data for numerous inflammation-based prognostic markers. Our future research will evaluate each laboratory parameter and develop a novel prognostic score.
In conclusion, our real-world data analysis demonstrated that 17 inflammation-based markers that previously reported held significant prognostic value for patients with metastatic pancreatic cancer. Among these markers, the mGPS exhibited the highest accuracy.
Acknowledgements
The authors would like to thank Dr Shinnichi Higashiue (chair of the Medical Corporation Tokushukai, Tokyo, Japan and General Incorporated Association Tokushukai, Tokyo, Japan) and Dr Hisaaki Afuso (chief advisor of the Medical Corporation Tokushukai, Tokyo, Japan) for their support in conducting clinical research within the Tokushukai Group, and Mr. Katsuhiko Ozaki (President of Tokushukai Information System, Inc., Osaka, Japan) for their assistance in using the medical database.
Funding
Funding: No funding was received.
Availability of data and materials
The data generated in the present study may be requested from the corresponding author.
Authors' contributions
RS, YI and MO made substantial contributions to the study design and conception. RS, YF, MS and MH were responsible for data acquisition. RS and YI interpreted the data and drafted the manuscript. KU, TM, KO, NS and HM provided advice on research design and aided in the critical interpretation of this research for critical content. RS and YI confirm the authenticity of all the raw data. NS and HM comprehensively reviewed and approved the final version of this manuscript. All authors have read and approved the final version of the manuscript.
Ethics approval and consent to participate
The project adhered to the ethical guidelines for medical and biological research involving human subjects in Japan and followed the principles of The Declaration of Helsinki. Approval for the study was obtained from the Ethics Committee of the Tokushukai Group in April 2020 (approval no. TGE01427-024), and the study was registered in the UMIN Clinical Trial Registry under the number UMIN000050590. Patients were provided with information using opt-out methods and no patient declared not to participate.
Patient consent for publication
Patient consent for publication was obtained through opt-out methods.
Competing interests
The authors declare that they have no competing interests.
Glossary
Abbreviations
Abbreviations:
AIC |
akaike information criterion |
BMI |
body mass index |
CALLY |
CRP albumin lymphocyte index |
CAR |
CRP-to-albumin ratio |
CIs |
confidence intervals |
dNLR |
derived neutrophil-to-lymphocyte ratio |
FOLFIRINOX |
fluorouracil, folic acid, oxaliplatin and irinotecan |
GPS |
Glasgow prognostic score |
HRs |
hazard ratios |
LIPI |
lung immune prognostic index |
LMR |
lymphocyte-to-monocyte ratio |
LMS |
lymphocyte-monocyte score |
mGPS |
modified Glasgow prognostic score |
NLR |
neutrophil-to-lymphocyte ratio |
NLS |
neutrophil-lymphocyte score |
NPS |
neutrophil-platelet score |
OS |
overall survival |
PI |
prognostic index |
PLR |
platelet-to-lymphocyte ratio |
PLS |
platelet-lymphocyte score |
PNI |
prognostic nutritional index |
S-1 |
tegafur/gimeracil/oteracil |
SII |
systemic immune-inflammation index |
SIRI |
systemic inflammation response index |
TREAD |
tokushukai real-world data |
UMIN |
university hospital medical information network |
References
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI | |
SEER 5-year relative survival rate, 2012–2018, . Cancer Statistics Explorer Network. National Cancer Institute; United States: https://seer.cancer.gov/statistics-network/explorer/application.htmlApril 1–2023 | |
Cancer Information Service, National Cancer Center, Japan and National Cancer Registry (In Japanese) (Ministry of Health, Labour and Welfare), . https://ganjoho.jp/reg_stat/statistics/data/dl/en.htmlApril 1–2023 | |
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI | |
Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, Isayama H and Boku N: Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 105:1321–1326. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, et al: A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 81:1017–1023. 2018. View Article : Google Scholar : PubMed/NCBI | |
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI | |
Shimoyama R, Imamura Y, Uryu K, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Ohtani K, Shinozaki N and Minami H: Real-world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real-world data project. Mol Clin Oncol. 19:982023. View Article : Google Scholar : PubMed/NCBI | |
McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 67:257–262. 2008. View Article : Google Scholar : PubMed/NCBI | |
Buzby GP, Mullen JL, Matthews DC, Hobbs C and Rosato EF: Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 139:160–167. 1980. View Article : Google Scholar : PubMed/NCBI | |
McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI | |
Dolan RD, McSorley ST, Horgan PG, Laird B and McMillan DC: The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 116:134–146. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shimoyama R, Imamura Y, Uryu K, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Ohtani K, Shinozaki N and Minami H: Real-world outcomes of systemic therapy in Japanese patients with cancer (Tokushukai REAl-world data project: TREAD): Study protocol for a nationwide cohort study. Healthcare (Basel). 10:21462022. View Article : Google Scholar : PubMed/NCBI | |
Eba J and Nakamura K: Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. Jpn J Clin Oncol. 52:539–544. 2022. View Article : Google Scholar : PubMed/NCBI | |
National Cancer Registry (Ministry of Health, Labour and Welfare), tabulated by Cancer Information Service, National Cancer Center, Japan, . https://ganjoho.jp/reg_stat/statistics/data/dl/en.htmlApril 1–2023 | |
Onodera T, Goseki N and Kosaki G: Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 85:1001–1005. 1984.(In Japanese). PubMed/NCBI | |
Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030. 2003. View Article : Google Scholar : PubMed/NCBI | |
Fairclough E, Cairns E, Hamilton J and Kelly C: Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond). 9:30–33. 2009. View Article : Google Scholar : PubMed/NCBI | |
Nakahara K, Monden Y, Ohno K, Fujii Y, Hashimoto J, Kitagawa Y and Kawashima Y: Importance of biologic status to the postoperative prognosis of patients with stage III nonsmall cell lung cancer. J Surg Oncol. 36:155–160. 1987. View Article : Google Scholar : PubMed/NCBI | |
Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F and Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI | |
Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, et al: The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 25:1502–1509. 2011. View Article : Google Scholar : PubMed/NCBI | |
Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG and Clarke SJ: A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 107:695–699. 2012. View Article : Google Scholar : PubMed/NCBI | |
Watt DG, Proctor MJ, Park JH, Horgan PG and McMillan DC: The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers. PLoS One. 10:e01421592015. View Article : Google Scholar : PubMed/NCBI | |
Dolan RD, McSorley ST, Park JH, Watt DG, Roxburgh CS, Horgan PG and McMillan DC: The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 119:40–51. 2018. View Article : Google Scholar : PubMed/NCBI | |
Dolan RD, Alwahid M, McSorley ST, Park JH, Stevenson RP, Roxburgh CS, Horgan PG and McMillan DC: A comparison of the prognostic value of composite ratios and cumulative scores in patients with operable rectal cancer. Sci Rep. 10:179652020. View Article : Google Scholar : PubMed/NCBI | |
Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H, Sharma R and Small D: The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 17:52–58. 2010.PubMed/NCBI | |
Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, Liu L, Meng Z, Wang P and Chen Z: A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 122:2158–2167. 2016. View Article : Google Scholar : PubMed/NCBI | |
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, et al: Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 4:351–357. 2018. View Article : Google Scholar : PubMed/NCBI | |
Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, et al: Immunonutritive scoring for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: Evaluation of the CALLY index. Cancers (Basel). 13:50182021. View Article : Google Scholar : PubMed/NCBI | |
Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 90:1704–1706. 2004. View Article : Google Scholar : PubMed/NCBI | |
McMillan DC, Crozier JEM, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI | |
Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y and Kusunoki M: Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2:95–101. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, et al: Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 27:732–738. 2016. View Article : Google Scholar : PubMed/NCBI | |
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, et al: Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 22:5487–5496. 2016. View Article : Google Scholar : PubMed/NCBI | |
Huang L, Han H, Zhou L, Chen X, Xu Q, Xie J, Zhan P, Chen S, Lv T and Song Y: Evaluation of the lung immune prognostic index in non-small cell lung cancer patients treated with systemic therapy: A retrospective study and meta-analysis. Front Oncol. 11:6702302021. View Article : Google Scholar : PubMed/NCBI | |
Zhang Q, Gong X, Sun L, Miao L and Zhou Y: The predictive value of pretreatment lactate dehydrogenase and derived neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: A meta-analysis. Front Oncol. 12:7914962022. View Article : Google Scholar : PubMed/NCBI | |
Banna GL, Di Quattro R, Malatino L, Fornarini G, Addeo A, Maruzzo M, Urzia V, Rundo F, Lipari H, De Giorgi U and Basso U: Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Clin Transl Oncol. 22:2130–2135. 2020. View Article : Google Scholar : PubMed/NCBI | |
Liu H, Yang XL, Yang XY, Dong ZR, Chen ZQ, Hong JG and Li T: The prediction potential of the pretreatment lung immune prognostic index for the therapeutic outcomes of immune checkpoint inhibitors in patients with solid cancer: A systematic review and meta-analysis. Front Oncol. 11:6910022021. View Article : Google Scholar : PubMed/NCBI | |
Strijker M, van Veldhuisen E, van der Geest LG, Busch OR, Bijlsma MF, Mohammad NH, Homs MY, van Hooft JE, Verheij J, de Vos-Geelen J, et al: Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Biomarkers. 26:325–334. 2021. View Article : Google Scholar : PubMed/NCBI | |
Ahmad J, Grimes N, Farid S and Morris-Stiff G: Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: A systematic review. Hepatobiliary Pancreat Dis Int. 13:474–481. 2014. View Article : Google Scholar : PubMed/NCBI |